Sanofi and Gilead moved down in the rankings of Scrip's top 100 pharmaceutical companies, based on 2017 pharma sales, while Johnson & Johnson, GSK and AbbVie moved up. Shire joined the top 20 just as it is about to be consumed by Takeda.
Scrip's latest rankings of the top 100 revenue earners in the medical technology industry, published in Outlook 2019, show the groups leading the global market tightening their grip further in 2017. This was partly a function of providers choosing to partner more and more with fewer suppliers who can offer a wider provision of services. But it was steady as she goes for most of the multinational medtechs, with some major exceptions, and there will be more M&A reflected in next year's rankings, based on 2018 revenues.
The Scrip 100 universe gathers FY 2017 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales.
The full Scrip 100 data set for 2019 is now available and includes data on R&D spending, total revenues, employee numbers and sales for 100 biopharmaceutical companies.
If you are a Scrip subscriber, click here to download the data in Excel format.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.